Statins Overlooked for Secondary Stroke Prevention
A nationwide study found onefifth of patients discontinued statins 3 to 6 months after discharge for an ischemic stroke while another study found less than half were ever prescribed a statin upon...
View ArticleInternational Laboratories LLC Issues Voluntary Nationwide Recall of one 1...
ST. PETERSBURG Fla. Aug. 10 2017 PRNewswire International Laboratories LLC is voluntarily recalling one 1 Lot of Pravastatin Sodium Tablets USP 40 mg packaged in bottles of 30 tablets to the consumer...
View ArticlePravastatin Tablets Recalled Contain Antidepressant
One lot of the cholesterollowering statin was mislabeled and instead contains an antidepressant. Medscape Medical News
View ArticleStatin use among nursing home residents varies significantly
HealthDayStatin prescribing is considerable among nursing home residents with significant variation in prescribing seen across physicians according to a study published online Aug. 9 in the Journal of...
View ArticleStudy finds similar cost value of CAC testing widespread statin treatment
When it comes to choosing whether to initiate statin treatment similar clinical and economic consequences result if clinicians follow current guidelines or use coronary artery calcium CAC testing to...
View ArticleStatins in the Drinking Water
MedPage Today Not so fast. In Revolution and Revelation Milton Packer reveals a glaring inconsistency in the most recent battle in the ongoing statin wars
View ArticleRepatha Evolocumab Phase 3 Cognitive Function Study Results Published In The...
THOUSAND OAKS Calif. Aug. 16 2017 PRNewswire Amgen NASDAQAMGN today announced that the New England Journal of Medicine NEJM published results from the Repatha evolocumab cognitive function trial...
View ArticleEvolocumab doesn't affect cognition when added to statins
HealthDayThere is no significant difference in cognitive function for patients treated with evolocumab or placebo added to statin therapy according to a study published in the Aug. 17 issue of the New...
View ArticleAmgen To Present New Data From The Repatha Evolocumab Cardiovascular...
THOUSAND OAKS Calif. Aug. 21 2017 PRNewswire Amgen NASDAQAMGN today announced that new data from the Repatha evolocumab clinical trial program including three latebreaking scientific sessions will be...
View ArticleCholesterollowering drugs may fight infectious disease
That statin you've been taking to lower your risk of heart attack or stroke may one day pull double duty providing protection against a whole host of infectious diseases including typhoid fever...
View ArticleLipids Statin Treatment Linked to Revision Rate After Rotator Cuff Repair
Elevated lipid levels are associated with an increased revisionsurgery rate after arthroscopic rotatorcuff repair while statin use appears to mitigate that increase according to a database review....
View ArticleDiscontinuing statins after stroke increases risk of another
Stopping statin therapy after ischaemic stroke should be discouraged to avoid increased risk of another stroke.
View ArticleCholesterolLowering Drugs May Fight Infectious Diseases
This digitallycolorized scanning electron microscopic SEM image shows Salmonella bacteria red invading an immune cell yellow. Courtesy of CDC That statin you've been taking to lower your risk of heart...
View ArticleNew Economic Analysis Based On Repatha Evolocumab Outcomes Data Published In...
THOUSAND OAKS Calif. Aug. 23 2017 PRNewswire Amgen NASDAQAMGN today announced results from a new Repatha evolocumab economic analysis published in the Journal of the American Medical Association JAMA...
View ArticleRegeneron and Sanofi to Present New Analyses from Praluent alirocumab...
TARRYTOWN N.Y. and BRIDGEWATER N.J. Aug. 25 2017 PRNewswire Regeneron Pharmaceuticals Inc. NASDAQ REGN and Sanofi today announced new analyses from Praluent alirocumab Injection clinical trials will...
View ArticleWomen less likely to receive recommended statin doses to prevent...
Women at high risk of cardiovascular events are less likely to receive recommended statin doses for secondary prevention according to results from the DYSIS study presented today at ESC Congress.
View ArticleNew Repatha evolocumab Analysis Demonstrates Cardiovascular Outcomes...
THOUSAND OAKS Calif. Aug. 28 2017 PRNewswire Amgen NASDAQAMGN today announced a new analysis from the Repatha evolocumab cardiovascular outcomes study FOURIER that showed a statistically significant...
View ArticleResearchers identify strategies to optimize statin treatment for muscle symptoms
Statins are highly effective for preventing heart attacks by reducing lowdensity lipoprotein or "bad" cholesterol. However 10 to 20 percent of patients taking statins report musclerelated symptoms...
View ArticleLatest efficacy studies support use of Amgen's Repatha in conjunction with...
Michael JohnsenThere was no evidence of a leveling off of effect and no new safety concerns were identified in this analysis Amgen reported.read more
View Article